Vertex Pharmaceuticals Incorporated (VRTX) Shares are Down -0.94%

Vertex Pharmaceuticals Incorporated (VRTX) has risen sharply, recording gains of 0.09% in the past 4 weeks. However, the stock has corrected -0.94% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.3% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.9% and the fifty day Moving Average is 4.05%. Vertex Pharmaceuticals Incorporated is up 7.42% in the last three month period. Year-to-Date the stock performance stands at -22.84%.

Vertex Pharmaceuticals Incorporated (VRTX) : The most positive equity analysts on Vertex Pharmaceuticals Incorporated (VRTX) expects the shares to touch $155, whereas, the least positive believes that the stock will trade at $75 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $116.42 with an expected fluctuation of $20.26 from the mean.


Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): stock turned positive on Friday. Though the stock opened at $96.94, the bulls momentum made the stock top out at $98.34 level for the day. The stock recorded a low of $96.1323 and closed the trading day at $97.09, in the green by 0.74%. The total traded volume for the day was 731,131. The stock had closed at $96.38 in the previous days trading.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.